Marso 2016 — LEADER Liraglutide Cardiovascular Outcomes

New England Journal of Medicine·July 28, 2016

Steven P. Marso, Gilbert H. Daniels, Kirstine Brown-Frandsen, Peter Kristensen, John F. E. Mann, Nauck M. A., LEADER Steering Committee

Summary

LEADER showed liraglutide reduced major adverse cardiovascular events and mortality endpoints in high-risk patients with type 2 diabetes.

Study Details

Study Design

Randomized double-blind placebo-controlled cardiovascular outcomes trial

Indication

Type 2 diabetes with high cardiovascular risk

Intervention

Liraglutide up to 1.8 mg daily vs placebo

Species

Human

Sample Size

9,340 subjects

Risk of Bias Assessment

Sponsor-funded; CVOT